PCI Biotech Holding ASA
Oslo Stock Exchange PCIB.OL
PCI Biotech Holding ASA EBITDA for the year ending December 31, 2023: USD -2.18 M
-
PCI Biotech Holding ASA EBITDA for the year ending December 31, 2022 was USD -5.52 M, a 41.11% change year over year.
-
PCI Biotech Holding ASA EBITDA for the year ending December 31, 2021 was USD -9.37 M, a -15.42% change year over year.
-
PCI Biotech Holding ASA EBITDA for the year ending December 31, 2020 was USD -8.12 M, a 16.27% change year over year.
-
PCI Biotech Holding ASA EBITDA for the year ending December 31, 2019 was USD -9.69 M, a -88.32% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
| CEO | Mr. Ronny Skuggedal |
| IPO Date | June 23, 2008 |
| Location | Norway |
| Headquarters | UllernchaussEen 64 |
| Employees | 6 |
| Sector | Health Care |
| Industries | |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email